NorthWest Biotherapeutics Inc (NWBO)

[j e d]

I don’t think there’s any issues with the SAP or buy-in—that process took over a year and they wouldn’t have locked data without that being a shut case.

The reason for delay is likely that articles like this take an average of a year to publish, and a complicated trial like ours might take a bit longer. But, we’re within the likely range now, as it’s been about a year exactly from when they likely got data back from statisticians. In the meantime, FDA has been growing friendlier, manufacturing has been ramping up, Lancet article supports our strategy, the large loan repayment is behind us, etc etc.

I expect TLD, publication, and Sawston certification by end of January at the latest. If none of those three things happen by then I will consider shedding shares.

In three months max share price should be $4+, so I hardly care if we hit $1 again or even 87¢.